Adicet Bio (ACET) vs IGC Pharma (IGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IGC Pharma (IGC) has outperformed Adicet Bio (ACET) over the past year, losing 47.5% versus a loss of 77.8%. Over five years, IGC leads with a -87.6% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $19.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | IGC |
|---|---|---|
| Share price | $2.14 | $0.168 |
| Market cap | $20.03M | $19.60M |
| 1-day change | -13.01% | -8.70% |
| YTD return | -74.58% | -40.00% |
| 1-year return | -77.78% | -47.50% |
| 5-year return | -98.58% | -87.65% |
| EPS (TTM) | $-7.53 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.27M |
| Revenue growth (YoY) | — | -5.50% |
| Net income (latest FY) | $-116.80M | $-7.12M |
| Gross margin | — | 48.70% |
| Operating margin | — | -585.84% |
| Net margin | — | -560.35% |
| 52-week high | $11.15 | $0.36 |
| 52-week low | $2.12 | $0.08 |
| Distance from 52-week high | -80.81% | -53.33% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1527.57% | +3471.43% |
| Average volume | 271.05K | 615.25K |
| Shares outstanding | 9.36M | 116.69M |
| Employees | 102 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IGC has outperformed ACET by 30.3 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
ACET vs IGC FAQ
Which is bigger, Adicet Bio or IGC Pharma?
Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $19.60M for IGC Pharma (IGC).
Which stock has performed better over the past year, ACET or IGC?
IGC returned -47.50% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and IGC Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.